Update! And note date!
$Allakos(ALLK.US$ Allakos Announces First Patient Dosed in Phase 1 Trial of Ak006 in Chronic Spontaneous Urticaria! Top-Line Phase 1 Csu Results Expected at Year End 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
